Melinta Therapeutics’ $1 Billion Acquistion of Infectious Disease Business from The Medicines Company

Willkie and Cadwalader, Wickersham & Taft LLP advised on the deal Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here